About
The operating system for personalized therapeutics.
Why We Exist
The pharma model wasn't built for rare patients.
95% of rare disease patients have no approved treatment. 300+ million people worldwide are living with a rare condition. The pharma model wasn’t built for rare patients.
Nome combines a full-stack AI platform with regional infrastructure partnerships to change that. We turn every rare disease patient's genome into an actionable treatment plan and execute at the lowest cost and highest speed in the industry.
Our Story
The bottleneck isn't science. It's operational complexity.
Stevie Ringel
Founder & CEO · Rare Disease Patient
At 17, Stevie and his sister Natalie were both diagnosed with an ultra-rare KIZ-mutant inherited retinal disease. Traditional pharma had no options. With only 18 known US patients, there was no financial incentive to act.
Stevie spent a decade chasing down experts, reading papers, and pursuing every existing option — waiting for the call that a clinical trial existed. That call never came. But he discovered something crucial: gene-editing technologies were already working for diseases with the same genetic characteristics. The science existed — it just wasn't being applied to his family's condition.
He founded the Kizuna Foundation and started building a gene therapy himself. The science was possible. But the operational complexity was staggering — reconciling conflicting expert opinions, navigating labs and manufacturers built for big pharma contracts, and finding no infrastructure to move a therapy from "we could make this" to "here's your dose."
That gap is why Nome exists. The real bottleneck to personalizing medicine isn't science — it's operational complexity. Nome is the operating system that coordinates all the fragmented players: geneticists, research labs, manufacturers, regulators, and providers. AI makes this possible in ways that weren't feasible even two years ago.
Our Mission at Scale
Each treatment teaches the next.
This isn't just one family's problem. Personalized medicine is infinitely more complex than traditional drug development — every therapy starts with a unique patient and their specific mutation. Handling this complexity manually for thousands of patients is impossible. But AI can manage all of these variables at once, learning from each case to optimize the next.
As Nome's system orchestrates more therapies, it gets smarter about which approaches work best for each patient, which manufacturers are reliable, and where delays happen — making each subsequent treatment faster and cheaper.
Backed By
